Earnings Preannouncement for 2025
Filed with SSE · · 2 pages · Chinese
Beijing Hotgen Biotech Co. Ltd. on 6ix
Earlier from Beijing Hotgen Biotech
- Announcement on Plan to Sell Part of Repurchased Shares through Call Auction Transactions
- Announcement on Resolutions of the 5th Extraordinary General Meeting in 2025
- Announcement on Voluntary Disclosure of Recent Qualifications Obtained by the Joint-stock Company of the Company
- Announcement on Joint Investment in Yaojing Gene with a Related Party and Related Party Transaction
- Voluntary Disclosure Announcement on Designation as a National-Level "Little Giant" Enterprise (Specialized, Sophisticated, Distinctive, and Innovative)
Later from Beijing Hotgen Biotech
- Announcement on Preliminary Earnings Estimate for 2025
- Announcement on Voluntary Disclosure of the Completion of First Patient Enrollment and Dosing in the Phase Ib Clinical Trial of Innovative Drug AA001 Monoclonal Antibody for Alzheimer’s Disease by an Joint-stock Company
- Announcement on Voluntary Disclosure of Completion of the First Patient Enrollment and Dosing in the Phase II Clinical Trial of SGC001 Innovative Drug by a Subsidiary
- Announcement on Initial Sale of Repurchased Shares Through Call Auction
- Announcement on Progress in Disposal of Repurchased Shares
Follow Beijing Hotgen Biotech into a list and get an email when it puts out news.
Follow Beijing Hotgen Biotech